PDE4A and chronic obstructive pulmonary disease: Roflumilast is an orally-active, selective inhibitor phosphodiesterase isoform 4 (PDE4) and as such it is approved for treating inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).